• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.

作者信息

Dimopoulos M A, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas D C, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E

机构信息

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Department of Nephrology and Transplantation Unit, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Blood Cancer J. 2017 Jun 16;7(6):e571. doi: 10.1038/bcj.2017.49.

DOI:10.1038/bcj.2017.49
PMID:28622304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5520396/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffbc/5520396/c115308506b9/bcj201749f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffbc/5520396/c115308506b9/bcj201749f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffbc/5520396/c115308506b9/bcj201749f1.jpg

相似文献

1
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.新诊断的需要透析的骨髓瘤患者的预后：肾脏恢复、快速反应的重要性及生存获益
Blood Cancer J. 2017 Jun 16;7(6):e571. doi: 10.1038/bcj.2017.49.
2
Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis.新诊断需要血液透析的多发性骨髓瘤患者血液透析独立性高的相关影响因素。
J Clin Lab Anal. 2020 Feb;34(2):e23057. doi: 10.1002/jcla.23057. Epub 2019 Oct 30.
3
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.硼替佐米为基础的三联方案在新诊断的伴有严重肾功能衰竭或需要透析的骨髓瘤患者中，具有较高的透析独立性和快速肾功能恢复的可能性。
Am J Hematol. 2016 May;91(5):499-502. doi: 10.1002/ajh.24335. Epub 2016 Apr 4.
4
Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.接受长期透析的多发性骨髓瘤或轻链淀粉样变性患者的生存及肾脏恢复趋势
Clin J Am Soc Nephrol. 2016 Mar 7;11(3):431-41. doi: 10.2215/CJN.06290615. Epub 2016 Jan 4.
5
Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.单药达雷妥尤单抗治疗需要透析的复发难治性多发性骨髓瘤患者：一项西班牙回顾性多中心研究的结果
Br J Haematol. 2020 Sep;190(5):e289-e292. doi: 10.1111/bjh.16286. Epub 2019 Dec 2.
6
Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.多发性骨髓瘤患者在从依赖透析的急性肾损伤中恢复后，具有出色的长期预后。
Eur J Haematol. 2016 Jun;96(6):610-7. doi: 10.1111/ejh.12644. Epub 2015 Sep 16.
7
Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney.高截流血液透析与标准血液透析治疗多发性骨髓瘤肾损害的成本效果模型比较。
Curr Med Res Opin. 2011 Feb;27(2):383-91. doi: 10.1185/03007995.2010.543125. Epub 2010 Dec 23.
8
Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.高通量透析器在多发性骨髓瘤急性肾衰竭中的应用。
Nefrologia. 2012;32(1):35-43. doi: 10.3265/Nefrologia.pre2011.Nov.11094.
9
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.硼替佐米为基础的治疗联合高通量血液透析对伴有严重肾功能损害的初诊多发性骨髓瘤患者非常有效。
Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035.
10
Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.游离轻链血液透析对骨髓瘤管型肾病的影响：一项病例对照研究。
Hemodial Int. 2011 Oct;15(4):538-45. doi: 10.1111/j.1542-4758.2011.00587.x. Epub 2011 Aug 16.

引用本文的文献

1
Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.透析依赖与多发性骨髓瘤的不良预后相关：一项多中心回顾性队列研究。
Ther Adv Med Oncol. 2025 Aug 21;17:17588359251357682. doi: 10.1177/17588359251357682. eCollection 2025.
2
Clinical and Renal Outcomes in Multiple Myeloma with Involved Free Light Chains Exceeding 1000 mg/L at Diagnosis: Insights from an Indian Cohort.诊断时游离轻链超过1000mg/L的多发性骨髓瘤的临床和肾脏结局：来自印度队列的见解
Indian J Hematol Blood Transfus. 2025 Apr;41(2):340-348. doi: 10.1007/s12288-024-01858-z. Epub 2024 Sep 5.
3

本文引用的文献

1
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.在未经选择的多发性骨髓瘤患者独立队列中对修订的国际分期系统进行评估。
Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27.
2
Managing renal complications in multiple myeloma.多发性骨髓瘤的肾脏并发症管理。
Expert Rev Hematol. 2016 Sep;9(9):839-50. doi: 10.1080/17474086.2016.1210003. Epub 2016 Jul 22.
3
Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.
A rare case of IgA lambda multiple myeloma in a 32-year-old woman with t(14;16) translocation associated with kidney injury and non-albumin proteinuria.
一例罕见的伴有肾脏损伤和非白蛋白蛋白尿的 32 岁女性 IgA 入链多发性骨髓瘤，患者存在 t(14;16)易位。
BMC Nephrol. 2024 May 16;25(1):165. doi: 10.1186/s12882-024-03600-3.
4
Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.多发性骨髓瘤患者疾病相关表现及药物毒性的实际管理
Front Oncol. 2024 Mar 22;14:1282300. doi: 10.3389/fonc.2024.1282300. eCollection 2024.
5
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.复发/难治性多发性骨髓瘤的难治性患者：临床试验结果综述
EJHaem. 2023 Aug 2;4(4):1117-1131. doi: 10.1002/jha2.743. eCollection 2023 Nov.
6
Profile and outcome of multiple myeloma with and without HIV treated at a tertiary hospital in KwaZulu-Natal, South Africa.南非夸祖鲁-纳塔尔省一家三级医院治疗的伴或不伴 HIV 的多发性骨髓瘤患者的特征和转归。
PLoS One. 2023 Oct 25;18(10):e0287304. doi: 10.1371/journal.pone.0287304. eCollection 2023.
7
Multiple Myeloma and Kidney Impairment at Diagnosis: A Nephrological Perspective from an Eastern European Country.多发性骨髓瘤伴诊断时的肾功能损害：来自东欧国家的肾脏病学视角。
Medicina (Kaunas). 2023 Jul 18;59(7):1326. doi: 10.3390/medicina59071326.
8
Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China.透析依赖对合并肾功能损害的多发性骨髓瘤患者生存的影响：一项中国多中心研究
Am J Cancer Res. 2023 Apr 15;13(4):1571-1581. eCollection 2023.
9
Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA.美国多发性骨髓瘤和淀粉样变性患者肾移植的结果。
Nephrol Dial Transplant. 2022 Nov 23;37(12):2569-2580. doi: 10.1093/ndt/gfac196.
10
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.多发性骨髓瘤及前体疾病的流行病学、遗传学和治疗。
Int J Cancer. 2021 Dec 15;149(12):1980-1996. doi: 10.1002/ijc.33762. Epub 2021 Aug 30.
多发性骨髓瘤治疗的演变及其对透析独立性的影响：来自法国1999年至2014年队列的数据。
Blood Cancer J. 2016 Mar 25;6(3):e409. doi: 10.1038/bcj.2016.17.
4
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.国际骨髓瘤工作组关于骨髓瘤相关肾脏损害的诊断和管理建议。
J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.
5
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
6
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.新型药物问世后，严重肾功能损害的多发性骨髓瘤患者的生存率显著提高。
Ann Oncol. 2014 Jan;25(1):195-200. doi: 10.1093/annonc/mdt483.
7
Bortezomib-induced survival signals and genes in human proximal tubular cells.硼替佐米在人近端肾小管细胞中诱导的生存信号和基因。
J Pharmacol Exp Ther. 2008 Dec;327(3):645-56. doi: 10.1124/jpet.108.142604. Epub 2008 Sep 5.
8
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.接受含大剂量地塞米松方案治疗的新诊断多发性骨髓瘤患者肾衰竭的可逆性及新型药物的影响
Haematologica. 2007 Apr;92(4):546-9. doi: 10.3324/haematol.10759.
9
International uniform response criteria for multiple myeloma.多发性骨髓瘤的国际统一反应标准。
Leukemia. 2006 Sep;20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20.
10
Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.多发性骨髓瘤中的肾衰竭：可逆性及其对预后的影响。北欧骨髓瘤研究小组。
Eur J Haematol. 2000 Sep;65(3):175-81. doi: 10.1034/j.1600-0609.2000.90221.x.